AESCIN - 90 tablets The drug for venous insufficiency

AESCIN - 90 tablets The drug for venous insufficiency Description

Aescin - 90 tablets

Indications:
Aescin is a drug indicated for use in the treatment of chronic venous insufficiency, varicose veins of the lower extremities, haemorrhoids, treatment of phlebitis of the lower extremities, as well as the prevention and treatment of postoperative and traumatic hematomas and edema.

Properties:
Aesin has an anti-swelling and anti-inflammatory effect and improves the tone of blood vessels. It reduces the permeability of blood vessel walls. It is effective in the treatment of postoperative and traumatic edema. Aescin causes faster absorption of traumatic hematomas and reduces the likelihood of their occurrence in the postoperative period (especially after surgical procedures of the musculoskeletal system). Moreover, by sealing the endothelium of blood vessels, it improves venous-lymphatic circulation. The drug is also used in the prevention of thrombophlebitis in the postoperative period, as well as in the treatment of disorders of the venous circulation of the limbs and varicose veins of the lower extremities. Ingredients:


The active substance is alpha-escin. The other ingredients are: lactose monohydrate, potato starch, povidone, talc, magnesium stearate. Coating: talc, titanium dioxide (E 171), povidone, polysorbate 80, methacrylic acid and ethyl acrylate copolymer, sodium carboxymethyl cellulose, sunset yellow (E 110), silicone antifoam emulsion. Application: Aescin film-coated tablets are intended for oral use. Adults



: the usual dose of Aescin is 2 tablets 3 times a day, after a meal with plenty of liquid. Prophylactically, it can be used at least 16 hours before surgery. After 2-3 months of treatment, maintenance treatment can be used at a dose of 40 mg (2 tablets) twice a day. When using contraceptives, a double dose of alpha-escin can be taken. Important information: The drug should not be used if the patient is allergic to the active substance or any of the other ingredients, if the patient has severe renal insufficiency, in women during pregnancy and during breastfeeding. Packaging: 90 tablets. Marketing authorization holder: Teva Pharmaceuticals Polska Sp. z o. o. PO / CBG / 20/0013